Literature DB >> 11297024

Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.

C S Palmer1, J K Schmier, E Snyder, B Scott.   

Abstract

The purpose of this study was to derive patient preferences and utilities for outcomes associated with treatment of motor fluctuations, or 'off-time', for patients with Parkinson's disease (PD). Visual analog scale (VAS) and standard gamble (SG) approaches were used with 60 patients to determine patient preferences and utilities for 10 health state descriptions. Health state descriptions were categorized according to two factors: disease severity, and proportion of the day with 'off-time'. There were two representative levels of disease severity, based on Hoehn and Yahr stages 1.5 and 2.5: unilateral disease with no postural instability, and bilateral disease with some postural instability. These severity levels were combined with five levels of 'off-time' per day ranging from none to > 75% of the day. Patients' mean preference or utility for their own current health ranged from 0.65 +/- 0.20 (VAS) to 0.74 +/- 0.22 (SG). Patients assigned the lowest mean values to the health state description for Hoehn and Yahr stage 2.5 with 'off-time' for > 75% of the day (VAS: 0.17 +/- 0.17; SG: 0.49 +/- 0.27). The highest mean values were assigned to Hoehn and Yahr stage 1.5 with no 'off-time' (VAS: 0.83 +/- 0.17; SG: 0.85 +/- 0.18). The results of this study indicated patients with PD would likely seek treatment that would minimize the amount of 'off-time' experienced per day, and that patients were relatively risk averse.

Entities:  

Mesh:

Year:  2000        PMID: 11297024     DOI: 10.1023/a:1008903126315

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  23 in total

1.  The health burdens of Parkinson's disease.

Authors:  E A Chrischilles; L M Rubenstein; M D Voelker; R B Wallace; R L Rodnitzky
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

2.  The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research.

Authors:  L M Rubenstein; M D Voelker; E A Chrischilles; D C Glenn; R B Wallace; R L Rodnitzky
Journal:  Qual Life Res       Date:  1998-05       Impact factor: 4.147

3.  Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors:  H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

4.  Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

Authors:  C Jenkinson; V Peto; R Fitzpatrick; R Greenhall; N Hyman
Journal:  Age Ageing       Date:  1995-11       Impact factor: 10.668

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders.

Authors:  R Fitzpatrick; V Peto; C Jenkinson; R Greenhall; N Hyman
Journal:  Mov Disord       Date:  1997-11       Impact factor: 10.338

7.  Methodological issues of patient utility measurement. Experience from two clinical trials.

Authors:  M P Rutten-van Mölken; C H Bakker; E K van Doorslaer; S van der Linden
Journal:  Med Care       Date:  1995-09       Impact factor: 2.983

8.  Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

Authors:  P Martínez-Martín; A Gil-Nagel; L M Gracia; J B Gómez; J Martínez-Sarriés; F Bermejo
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

9.  Patients' experiences of Parkinson's disease.

Authors:  M Brod; G A Mendelsohn; B Roberts
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  1998-07       Impact factor: 4.077

Review 10.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner; S M Goldman
Journal:  Neurol Clin       Date:  1996-05       Impact factor: 3.806

View more
  14 in total

Review 1.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Authors:  Cicely Kerr; Emily J Lloyd; Charlotte E Kosmas; Helen T Smith; James A Cooper; Karissa Johnston; Emma McIntosh; Andrew J Lloyd
Journal:  Qual Life Res       Date:  2015-12-01       Impact factor: 4.147

3.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

Review 4.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

5.  Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Authors:  Huybert Groenendaal; Marcy L Tarrants; Christophe Armand
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

6.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.

Authors:  Alan Haycox; Christophe Armand; Susana Murteira; John Cochran; Clément François
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations.

Authors:  Michela Barichella; Chiara Savardi; Andrea Mauri; Agnieszka Marczewska; Antonella Vairo; Cinzia Baldo; Arianna Massarotto; Sara Elisabetta Cordara; Gianni Pezzoli
Journal:  Nutr Neurosci       Date:  2007 Jun-Aug       Impact factor: 4.994

9.  Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.

Authors:  Jenny M Norlin; Klas Kellerborg; Per Odin
Journal:  Pharmacoeconomics       Date:  2021-07-07       Impact factor: 4.981

10.  Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease.

Authors:  Heather L Benz; Brittany Caldwell; John P Ruiz; Anindita Saha; Martin Ho; Stephanie Christopher; Dawn Bardot; Margaret Sheehan; Anne Donnelly; Lauren McLaughlin; Brennan Mange; A Brett Hauber; Katrina Gwinn; William J Heetderks; Murray Sheldon
Journal:  MDM Policy Pract       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.